Allocations
EQT’s first US-dedicated fund, EQT Mid Market US, closed on 30 September with commitments of USD726 million.
The EQT Mid Market US fund applies a growth buyout investment strategy which involves developing and transforming good companies into stronger, more sustainable businesses.
The fund will make control and co-control investments in high-quality companies operating in sectors with strong underlying growth trends.
The fund will also leverage EQT’s network of over 250 industrial advisers and apply the firm's governance model and alignment principles to help support portfolio company growth.
Two acquisitions have already been made in the US by
Investment and advisory business Edition Capital has launched First Edition EIS, an investment fund that aims to provide growth support for businesses in the media and entertainment sectors.
The fund, which is targeting an initial raise of up to GBP20 million, will focus on the live entertainment, television, venues and immersive media sectors.
Edition Capital partner Harry Heartfield says: “We’re extremely excited to be launching ‘First Edition EIS’ and we’re very much looking forward to identifying the next big things in the media and entertainment sectors. The Edition Capital team is highly experienced in developing emerging brands and helping them
Calculus Capital, a private equity fund manager and Enterprise Investment Scheme and VCT provider, has sold its investment in Human Race, a UK mass participation sports company, to Amaury Sport Organisation (ASO).
ASO is the company behind Le Tour de France, the Schneider Electric Marathon de Paris and many other European sports events.
Human Race organises more than 30 mass participation events in the UK, including the London Winter Run, Windsor Triathlon and the new VitalityMove events run in partnership with Olympic champion Jessica Ennis-Hill.
More than one million participants have taken part in events organised by one
Law firm Paul Hastings has advised the Weber family on the sale of a majority interest in Weber Automotive to the independent private equity fund Ardian.
The transaction was signed after undergoing a competitive bidder process in which Ardian emerged as highest bidder.
The parties have agreed not to disclose the economic details of the transaction, which is subject to the approvals of antitrust authorities.
Given the global activities of Weber Automotive and its subsidiaries in Europe, the US and Asia, the further involvement of the Weber Family post-closing, and a very strong international tax and real estate
Management and technology consultancy Brickendon has merged with Spaarks, a software consultancy specialising in rapid technology-led business solutions.
The merger is expected to grow the combined business by 150 per cent over the next 12 months. The combined group will have an expanded range of solutions to further support clients in the financial services market.
Since Brickendon launched in 2010, the company has achieved 200 per cent growth per annum. It recently opened an office in New York City.
By consolidating its services with Spaarks, Brickendon will gain new global opportunities, including a foothold in Australia’s financial services
Omnia has entered the UK retail investor market with the launch of a new bond proposition – the Omnia Corporate Bond – which will provide the Swiss investment house with an alternative source of finance to fund its investment activities.
Omnia says the bond also creates an opportunity for investors seeking an attractive rate of income, or with an appetite for new investment solutions, to share in an exciting new private equity model, whilst enjoying a highly competitive and fixed rate of return.
Launched by Omnia Bonds plc, a UK-based subsidiary of Omnia Private Equity, the five-year asset-backed bond
Investment firm Fundamental Asset Management, specialists in the AIM market, reports that despite a quiet month for new issues, the market has seen strong performance in share prices for many companies.
Fundamental’s Chris Boxall says that new issue activity on AIM virtually ground to a halt in September with only one genuine new arrival Aura Energy, an Australian based uranium company. With eight cancellations there were only 1,000 companies listed at the end of the month. Yet despite the declining numbers the overall market capitalisation of AIM continued to surge higher (GBP82.98 billion from GBP80.57 billion in August) with strong share
BioVentures Investors has held the closing of its fourth fund at USD87 million.
The Wellesley, Massachusetts, venture fund will invest in high-value-added medical technology enterprises (MedTech) such as medical devices and diagnostics.
The fund’s focus is on technology with the potential to provide important benefits to patients, physicians and healthcare institutions, as well as significant returns to investors.
The fund’s management includes BioVentures Investors founders Marc Goldberg and Peter Feinstein; Jeff Barnes, managing director and partner; and Walter Gilbert as senior partner. Goldberg will serve as managing partner.
Since its initial close, Fund IV has made four
KKR and TowerBrook are acquiring a minority stake in cloud provider OVH for EUR250 million of growth capital.
The funds will allow OVH to take advantage of the expanding market for cloud and internet infrastructure services, while also broadening its customer base and services in new geographies.
The Klaba family will retain the majority stake in the company and will continue, together with OVH management, to lead the company, its strategy and operations.
The infrastructure-as-a-service (IaaS) and platform-as-a-service (PaaS) markets are expected to continue to grow rapidly, driven in large part by the exploding demand for cloud services.
Monroe Capital acted as sole lead arranger and administrative agent on the funding of a senior credit facility to support the acquisition of ProPharma Group by private equity sponsor Linden Capital Partners.
Founded in 2001 and based in Overland Park, Kansas, ProPharma is a provider of outsourced medical information, pharmacovigilance and regulatory compliance consulting services to customers in the pharmaceutical, biotechnology, and medical device industries.
The company has grown to a global organisation operating five contact centres across the US, Europe and Australia.
ProPharma serves a customer base which includes many of the world’s largest and well-known biopharmaceutical
Events
12 November, 2026 – 8:00 am
12 November, 2026 – 5:00 pm
